Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Depreciation and Depletion (2016 - 2025)

Historic Depreciation and Depletion for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to $600000.0.

  • Cartesian Therapeutics' Depreciation and Depletion rose 10000.0% to $600000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 15555.56%. This contributed to the annual value of $1.2 million for FY2024, which is 7142.86% up from last year.
  • Latest data reveals that Cartesian Therapeutics reported Depreciation and Depletion of $600000.0 as of Q3 2025, which was up 10000.0% from $600000.0 recorded in Q2 2025.
  • Over the past 5 years, Cartesian Therapeutics' Depreciation and Depletion peaked at $600000.0 during Q1 2025, and registered a low of $100000.0 during Q1 2021.
  • In the last 5 years, Cartesian Therapeutics' Depreciation and Depletion had a median value of $200000.0 in 2021 and averaged $263157.9.
  • As far as peak fluctuations go, Cartesian Therapeutics' Depreciation and Depletion tumbled by 5000.0% in 2021, and later skyrocketed by 20000.0% in 2024.
  • Cartesian Therapeutics' Depreciation and Depletion (Quarter) stood at $200000.0 in 2021, then changed by 0.0% to $200000.0 in 2022, then changed by 0.0% to $200000.0 in 2023, then surged by 150.0% to $500000.0 in 2024, then grew by 20.0% to $600000.0 in 2025.
  • Its Depreciation and Depletion was $600000.0 in Q3 2025, compared to $600000.0 in Q2 2025 and $600000.0 in Q1 2025.